Next 10 |
2024-05-09 00:53:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerevel Therapeutics Hldg (NASDAQ: CERE ) just reported results for the second quarter of 2024. Cerevel Therapeutics Hldg reported earnings per share of -73 cents. This wa...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-04-25 08:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...
2024-04-18 07:00:23 ET More on AbbVie AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore Ab...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to ...
2024-04-04 15:12:29 ET More on AbbVie AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Aldeyra gains as Oppenheime...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...
News, Short Squeeze, Breakout and More Instantly...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...